logo

Inovio Pharmaceuticals Inc. (INO)



Trade INO now with
  Date
  Headline
2/2/2023 8:00:52 AM INOVIO Reports Positive Phase 1b Results For INO-4201 As Ebola Booster For RVSV-ZEBOV
1/31/2023 8:04:47 AM INOVIO Announces Cost-saving Measures Include 11% Headcount Reduction; Annual Savings Expected To Be About $4.3 Mln
11/8/2022 4:08:08 PM INOVIO Q3 Loss/share $0.15 Vs. Loss $0.29 Year Ago
10/13/2022 8:01:11 AM INOVIO Reports Positive Interim Phase 1/2 Results For INO-3107 For Recurrent Respiratory Papillomatosis
9/1/2022 8:01:10 AM INOVIO Reports Inducement Grants Under Inducement Plan
9/1/2022 8:00:00 AM INOVIO Reports Inducement Grants Under Inducement Plan (Press Release)
8/9/2022 4:10:55 PM INOVIO Q2 Loss/share $0.46 Vs. Loss $0.39 Year Ago
7/19/2022 8:04:35 AM INOVIO Announces Reorganization, Incl 18% Workforce Reduction In Full-time Employees And 86% Reduction In Contractors
6/27/2022 8:02:26 AM INOVIO Appoints Michael Sumner As Chief Medical Officer
5/27/2022 8:03:55 AM INOVIO Announces Survival Results For INO-5401 + INO-9012 In With Libtayo In Patients With Newly Diagnosed GBM At ASCO